These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3015648)

  • 1. No response improvement after sequential chemotherapy for small cell lung cancer.
    Postmus PE; Sleijfer DT; Meinesz AF; Kerstjens HA; Lo GT; Sluiter HJ
    Eur J Respir Dis; 1986 Apr; 68(4):279-85. PubMed ID: 3015648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung].
    Navarro M; Mur E; Jolis L; Bellmunt J; Bodi R; Solé LA; Rubio D
    Rev Clin Esp; 1991 Oct; 189(5):209-12. PubMed ID: 1666192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide (VP-16) containing combination chemotherapy for treatment of patients with small cell lung cancer.
    Behera D; Jindal SK; Sharma SC
    Indian J Chest Dis Allied Sci; 1995; 37(1):15-9. PubMed ID: 16892733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC; McCrystal MR; Christmas TI
    N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin and etoposide alternating with vincristine, doxorubicin and cyclophosphamide in patients with small cell lung cancer.
    Littlewood TJ; Smith AP; Anderson G; Chappell AG; James KW
    Eur J Respir Dis; 1985 Oct; 67(4):294-300. PubMed ID: 3000808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy induction, consolidation radiotherapy and maintenance alternating chemotherapy in small cell carcinoma of the lung.
    Warner-Efrati E; Sulkes A; Weshler Z; Peretz T; Ben-Yosef R; Catane R; Biran S
    Isr J Med Sci; 1988; 24(9-10):593-8. PubMed ID: 2849598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
    Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).
    Yuen AR; Fuks JZ; Ettinger DS; Chang AY; Ruckdeschel JC; Phan SC; Blum RH
    Cancer J Sci Am; 2000; 6(1):34-9. PubMed ID: 10696737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T
    Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
    Leighl NB; Goss GD; Lopez PG; Burkes RL; Dancey JE; Rahim YH; Rudinskas LC; Pouliot JF; Rodgers A; Pond GR; Shepherd FA
    Lung Cancer; 2006 Jun; 52(3):327-32. PubMed ID: 16597474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung.
    Remick SC; Neville AJ; Willson JK
    Cancer Treat Rep; 1987 Jun; 71(6):575-80. PubMed ID: 3034422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy for small cell lung cancer.
    Sufarlan AW; Zainudin BM
    Med J Malaysia; 1993 Jun; 48(2):166-70. PubMed ID: 8394502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group.
    Urban T; Chastang C; Lebas FX; Duhamel JP; Adam G; Darse J; Bréchot JM; Lebeau B
    Cancer; 1999 Dec; 86(11):2238-45. PubMed ID: 10590363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial.
    Gatzemeier U; Pawel JV; Laumen R; Hossfeld DK; Neuhauss R
    Semin Oncol; 1994 Jun; 21(3 Suppl 6):31-5. PubMed ID: 8052871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
    Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer.
    Buccheri G; Ferrigno D; Curcio A; Vola F; Mattalia E
    Chemioterapia; 1986 Feb; 5(1):53-7. PubMed ID: 3955784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.